Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 1.00 |
| ▸ | ABL1 | P00519 | 9/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 4/20 | 1.00 |
| ▸ | PRKDC | P78527 | 4/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 3/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 3/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 0.72 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | MTOR | P42345 | 2/20 | 0.72 |
| ▸ | HCK | P08631 | 1/20 | 0.72 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390060 | 1.00 | SRC (1.00) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL29390926 | 1.00 | SRC (1.00) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL17637855 | 0.89 | SRC (0.80) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL14617291 | 0.87 | SRC (1.00) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL14617304 | 0.86 | SRC (1.00) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL14617301 | 0.86 | SRC (0.89) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL14617294 | 0.85 | SRC (1.00) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL3610160 | 0.85 | SRC (0.95) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL409031 | 0.84 | SRC (1.00) | SRCABL1PIK3CDPRKDCPIK3CA | |
| SCHEMBL13845116 | 0.84 | SRC (0.72) | SRCABL1PIK3CDPRKDCPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | claimed |
| EP-2528919-B1 | COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES | UNIV WASHINGTON (US) | 2016-11-02 | — | — | EP | claimed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11311609-B2 | Regulating chimeric antigen receptors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2020-07-16 | — | — | US | disclosed |
| US-20090253717-A1 | Inhibitors of p97 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-08 | — | — | US | disclosed |
| US-20090253717-A1 | Inhibitors of p97 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-08 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| EP-1140938-B1 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | UNIV PRINCETON (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1321467-A2 | High affinity inhibitors for target validation and uses thereof | Princeton University (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | PRINCETON UNIVERSITY | 2003-04-17 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885PIK3CD 167/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | SRC 766/4885ABL1 1463/4885PIK3CD 2674/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SRC 1396/4885ABL1 3456/4885PIK3CD 3419/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | SRC 1396/4885ABL1 3456/4885PIK3CD 3419/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | SRC 3905/4885ABL1 2538/4885PIK3CD 4733/4885 |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885PIK3CD 167/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | SRC 766/4885ABL1 1463/4885PIK3CD 2674/4885 |
| US-20090253717-A1 | Inhibitors of p97 | TMEM97, CDC37, HSP90B1 | SRC 1172/4885ABL1 50/4885PIK3CD 3053/4885 |
| US-11311609-B2 | Regulating chimeric antigen receptors | NFATC1, TNFRSF9, IL2RA | SRC 303/4885ABL1 2453/4885PIK3CD 2659/4885 |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | TNF, TSLP, IL1B | SRC 3920/4885ABL1 2533/4885PIK3CD 3413/4885 |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | SRC, MARCKS, TEC | SRC 1/4885ABL1 18/4885PIK3CD 514/4885 |
| US-20200223803-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | SRC 132/4885ABL1 1181/4885PIK3CD 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.